Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: A comparison of prognostic value and reproducibility

Histopathology

Volumn 65, Issue 2, 2014, Pages 252-260

  Ekholm, Maria ^a,b   Beglerbegovic, Sanda ^c   Grabau, Dorthe ^b,d   Lövgren, Kristina ^b   Malmström, Per ^b,d   Hartman, Linda ^b,e   Fernö, Mårten ^b  

^a RYHOV COUNTY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c CENTRAL HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e South Swedish Regional   (Sweden)

Author keywords

Breast neoplasms; Cell proliferation; Ki67 antigen; MIB1; Prognosis; Reproducibility of results; SP6

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MIB1 ANTIBODY; PROGESTERONE RECEPTOR; SP6 ANTIBODY; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; MIB-1 ANTIBODY; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SIZE; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; REPRODUCIBILITY; TISSUE MICROARRAY; AGED; ANTIBODY SPECIFICITY; BREAST TUMOR; DIAGNOSTIC USE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904395177     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12392     Document Type: Article

References (22)

1. Gerdes J, Lemke H, Baisch H et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 1984; 133; 1710-1715.
2. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 2000; 182; 311-322.
3. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 2009; 101; 736-750.
4. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 2011; 22; 1736-1747.
5. Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 2013; 24; 2206-2223.
6. Cattoretti G, Becker MH, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol. 1992; 168; 357-363.
7. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J. Clin. Oncol. 2005; 23; 7212-7220.
8. Dowsett M, Nielsen TO, A'Hern R et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J. Natl Cancer Inst. 2011; 103; 1656-1664.
9. Varga Z, Diebold J, Dommann-Scherrer C et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS ONE 2012; 7; e37379.
10. Rossi S, Laurino L, Furlanetto A et al. Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am. J. Clin. Pathol. 2005; 124; 295-302.
11. Wong SC, Chan JK, Lo ES et al. The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry. Arch. Pathol. Lab. Med. 2007; 131; 1047-1055.
12. Zabaglo L, Salter J, Anderson H et al. Comparative validation of the SP6 antibody to Ki67 in breast cancer. J. Clin. Pathol. 2010; 63; 800-804.
13. Faratian D, Munro A, Twelves C et al. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma. Histopathology 2009; 54; 254-257.
14. Leonardo E, Volante M, Barbareschi M et al. Cell membrane reactivity of MIB-1 antibody to Ki67 in human tumors: fact or artifact? Appl. Immunohistochem. Mol. Morphol. 2007; 15; 220-223.
15. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 2010; 28; 2784-2795.
16. Malmstrom P, Bendahl PO, Boiesen P et al. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J. Clin. Oncol. 2001; 19; 2010-2019.
17. Malmstrom P, Holmberg L, Anderson H et al. Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. Eur. J. Cancer 2003; 39; 1690-1697.
18. Hilsenbeck SG, Ravdin PM, de Moor CA et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res. Treat. 1998; 52; 227-237.
19. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
20. Klintman M, Bendahl PO, Grabau D et al. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod. Pathol. 2010; 23; 251-259.
21. Voros A, Csorgo E, Nyari T et al. An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications. Pathobiology 2013; 80; 111-118.
22. Ruiz C, Seibt S, Al Kuraya K et al. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int. J. Cancer 2006; 118; 2190-2194.